In vivo immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against Brucella melitensis in BALB/c mice

[1]  Gunjan Tiyyagura,et al.  Development and Evaluation , 2021 .

[2]  M. Tahmoorespur,et al.  Immunogenicity evaluation of plasmids encoding Brucella melitensis Omp25 and Omp31 antigens in BALB/c mice , 2018, Iranian journal of basic medical sciences.

[3]  M. Naghavi,et al.  Design and Production of a Novel Recombinant Chimeric IL2-Omp31 Antigen against Brucella Infection. , 2018, Archives of Razi Institute.

[4]  A. Haghparast,et al.  Engineering, Cloning and Expression of DNA Sequence Coding of OMP31 Epitope of Brucella melitensis linked to IL-2 in Escherichia coli , 2018, International Journal of Infection.

[5]  S. Yousefi,et al.  Evaluation of immune responses induced by polymeric OMP25-BLS Brucella antigen. , 2018, Microbial pathogenesis.

[6]  L. Saveanu,et al.  Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets , 2015, Front. Immunol..

[7]  S. Grinstein,et al.  Contrasting phagosome pH regulation and maturation in human M1 and M2 macrophages , 2014, Molecular biology of the cell.

[8]  N. Demaurex,et al.  Hv1 proton channels differentially regulate the pH of neutrophil and macrophage phagosomes by sustaining the production of phagosomal ROS that inhibit the delivery of vacuolar ATPases , 2014, Journal of leukocyte biology.

[9]  Chuangfu Chen,et al.  Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep. , 2014, Vaccine.

[10]  M. Marks,et al.  Presentation of Phagocytosed Antigens by MHC Class I and II , 2013, Traffic.

[11]  J. Skyberg,et al.  Progress in Brucella vaccine development , 2013, Frontiers in Biology.

[12]  Kairong Cui,et al.  Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. , 2012, Immunity.

[13]  Fernanda S. Oliveira,et al.  Host Susceptibility to Brucella abortus Infection Is More Pronounced in IFN-γ knockout than IL-12/β2-Microglobulin Double-Deficient Mice , 2011, Clinical & developmental immunology.

[14]  J. Demengeot,et al.  Regulatory T Cells Accumulate in the Lung Allergic Inflammation and Efficiently Suppress T-Cell Proliferation but Not Th2 Cytokine Production , 2011, Clinical & developmental immunology.

[15]  S. Gordon,et al.  Alternative activation of macrophages: an immunologic functional perspective. , 2009, Annual review of immunology.

[16]  G. Shukla,et al.  Immunogenicity of Recombinant Omp28 from Brucella Melitensis in Mice , 2008 .

[17]  M. Russo,et al.  Role of Endogenous IFN-γ in Macrophage Programming Induced by IL-12 and IL-18 , 2007 .

[18]  M. Russo,et al.  Role of endogenous IFN-gamma in macrophage programming induced by IL-12 and IL-18. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[19]  S. Estein,et al.  Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection , 2005, Infection and Immunity.

[20]  J. Lohr,et al.  Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen , 2005, The Journal of experimental medicine.

[21]  S. Estein,et al.  A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response , 2005, Infection and Immunity.

[22]  G. Buchan,et al.  Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy. , 2005, Vaccine.

[23]  A. Cloeckaert,et al.  Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. , 2004, Vaccine.

[24]  B. Rouse,et al.  Molecular adjuvants for mucosal immunity , 2004, Immunological reviews.

[25]  P. Kremsner,et al.  Antibody response inPlasmodium vinckei malaria after treatment with chloroquine and adjuvant interferon-γ , 2004, Parasitology Research.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[27]  L. Rogge.  A Genomic View of Helper T Cell Subsets , 2002, Annals of the New York Academy of Sciences.

[28]  E. Shevach,et al.  Role of IFN-γ in Th1 Differentiation: IFN-γ Regulates IL-18Rα Expression by Preventing the Negative Effects of IL-4 and by Inducing/Maintaining IL-12 Receptor β2 Expression , 2002, The Journal of Immunology.

[29]  Martin Raff,et al.  T Cells and MHC Proteins , 2002 .

[30]  A. Cloeckaert,et al.  Minor Nucleotide Substitutions in the omp31 Gene ofBrucella ovis Result in Antigenic Differences in the Major Outer Membrane Protein That It Encodes Compared to Those of the OtherBrucella Species , 2001, Infection and Immunity.

[31]  T. Mosmann,et al.  In Vivo Priming of Cd4 T Cells That Produce Interleukin (Il)-2 but Not IL-4 or Interferon (Ifn)-γ, and Can Subsequently Differentiate into IL-4–Or IFN-γ–Secreting Cells , 2001, The Journal of experimental medicine.

[32]  D. Scott,et al.  Immunity and protection against Brucella abortus. , 2001, Microbes and infection.

[33]  S. Ståhl,et al.  Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. , 1999, Journal of biotechnology.

[34]  A. Cloeckaert,et al.  Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein , 1996, Infection and immunity.

[35]  S. Hinuma,et al.  Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. , 1994, The Journal of infectious diseases.

[36]  M. Modolell,et al.  In vivo depletion of interferon-gamma leads to susceptibility of A/J mice to mouse hepatitis virus 3 infection , 1992, Immunobiology.

[37]  G. Gustafson,et al.  Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. , 1992, Research in immunology.

[38]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[39]  T. Kasahara,et al.  Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. , 1983, Journal of immunology.